Rigel Pharmaceuticals, Inc.
448 articles about Rigel Pharmaceuticals, Inc.
-
Rigel Pharmaceuticals, Inc.'s (JOBS) R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
7/27/2009
-
Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis
7/23/2009
-
Rigel Pharmaceuticals, Inc.'s R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial Expected and Manageable Safety Profile Demonstrated in TASKi2
7/10/2009
-
Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
7/9/2009
-
Rigel Pharmaceuticals, Inc.'s R788 Evaluated in Phase 2 Trial in Multiple Cancers
6/1/2009
-
Rigel Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
5/5/2009
-
Rigel Pharmaceuticals, Inc. and Proteros biostructures GmbH Extend Research Collaboration
4/6/2009
-
Rigel Pharmaceuticals, Inc. to Present at Citi's Biotech Day
3/30/2009
-
Rigel Pharmaceuticals, Inc. Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
3/13/2009
-
Rigel Pharmaceuticals, Inc. Announces Fourth Quarter and Year End 2008 Financial Results
2/24/2009
-
Rigel Pharmaceuticals, Inc. to Present at Biotechnology Industry Organization (BIO) CEO & Investor Conference
2/5/2009
-
Rigel Pharmaceuticals, Inc. to Present at Keystone Symposia Conference
1/23/2009
-
Phase 2 Results of Rigel Pharmaceuticals, Inc.'s R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL Results To Be Presented Today at American Society of Hematology Meeting in San Francisco
12/8/2008
-
Rigel Pharmaceuticals, Inc. to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at American Society of Hematology
12/3/2008
-
Rigel Pharmaceuticals, Inc.'s R788 Phase 2a Results Published in Arthritis and Rheumatism First of Phase 2b Studies Completes Patient Screening for Enrollment
11/11/2008
-
Rigel Pharmaceuticals, Inc. to Present at the 2008 Credit Suisse Healthcare Conference
11/11/2008
-
Rigel Pharmaceuticals, Inc. Shares Tank on Arthritis Data
10/29/2008
-
Rigel Pharmaceuticals, Inc. to Present at Thomas Weisel Partners Healthcare Conference
8/27/2008
-
Rigel Pharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
8/6/2008
-
Rigel Pharmaceuticals, Inc. Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis TASKI 2 and TASKI 3 Trials Launch Globally
6/12/2008